Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192)
China
· Delayed Price · Currency is CNY 35.78
-1.81 (-4.82%)
Sep 6, 2024, 4:00 PM CST
Dizal (Jiangsu) Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Net Income | -938.21 | -1,108 | -736 | -669.88 | -586.61 | -445.75 | Upgrade
|
| Depreciation & Amortization | 62.41 | 63.62 | 58.43 | 53.72 | 29.82 | 23.32 | Upgrade
|
| Other Amortization | 14.87 | 9.06 | 4.64 | 1.86 | 0.74 | 0.02 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.01 | 0.01 | -0.02 | - | -198.82 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -16.83 | -22.52 | -42.16 | -2.37 | -2.65 | -0.45 | Upgrade
|
| Stock-Based Compensation | 161.6 | 196.61 | 27.89 | 61.97 | 400.52 | - | Upgrade
|
| Provision & Write-off of Bad Debts | 0.77 | 0.4 | -0.02 | 0 | -0.01 | -0.03 | Upgrade
|
| Other Operating Activities | -77.94 | 6.6 | -5.17 | 9.4 | 17.68 | -3.14 | Upgrade
|
| Change in Accounts Receivable | -59.55 | -57.22 | -0.72 | -17.93 | -1.14 | 3.22 | Upgrade
|
| Change in Inventory | -18.35 | -18.4 | -5.07 | - | - | - | Upgrade
|
| Change in Accounts Payable | 42.72 | -38.33 | 94.83 | 70.93 | -69.54 | 57.18 | Upgrade
|
| Operating Cash Flow | -828.5 | -967.88 | -603.37 | -492.28 | -410.01 | -365.63 | Upgrade
|
| Capital Expenditures | -40.2 | -32.13 | -73.78 | -8.98 | -211.73 | -13.83 | Upgrade
|
| Sale of Property, Plant & Equipment | 0 | 0 | 0 | - | - | - | Upgrade
|
| Investment in Securities | 240.47 | 643.32 | 458.34 | -1,620 | -78 | 199 | Upgrade
|
| Other Investing Activities | - | - | - | 1.68 | 204.69 | 3.4 | Upgrade
|
| Investing Cash Flow | 200.27 | 611.19 | 384.56 | -1,627 | -85.04 | 188.57 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 19.54 | - | - | Upgrade
|
| Long-Term Debt Issued | - | 338.23 | - | - | - | - | Upgrade
|
| Total Debt Issued | 674.05 | 338.23 | - | 19.54 | - | - | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -19.54 | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -26.32 | -22.14 | -18.01 | - | - | Upgrade
|
| Total Debt Repaid | -155.35 | -26.32 | -22.14 | -37.55 | - | - | Upgrade
|
| Net Debt Issued (Repaid) | 518.7 | 311.91 | -22.14 | -18.01 | - | - | Upgrade
|
| Issuance of Common Stock | 39.09 | 1.25 | 3.75 | 2,022 | 814.6 | 352.62 | Upgrade
|
| Common Dividends Paid | -11.05 | -3.38 | - | - | - | - | Upgrade
|
| Other Financing Activities | 99.45 | -1.53 | -14.88 | -22.45 | - | - | Upgrade
|
| Financing Cash Flow | 646.2 | 308.25 | -33.26 | 1,981 | 814.6 | 352.62 | Upgrade
|
| Foreign Exchange Rate Adjustments | 3.46 | 0.97 | 9.52 | -6.33 | -17.4 | 1.04 | Upgrade
|
| Net Cash Flow | 21.43 | -47.47 | -242.56 | -144.78 | 302.14 | 176.6 | Upgrade
|
| Free Cash Flow | -868.7 | -1,000 | -677.15 | -501.26 | -621.75 | -379.45 | Upgrade
|
| Free Cash Flow Margin | -294.64% | -1095.44% | - | -4873.51% | -2239.65% | -925.10% | Upgrade
|
| Free Cash Flow Per Share | -2.11 | -2.46 | -1.67 | -1.39 | -1.73 | - | Upgrade
|
| Cash Interest Paid | - | - | - | 0.05 | - | - | Upgrade
|
| Cash Income Tax Paid | 7.43 | -5.18 | -68.69 | -25.17 | -21.93 | 0.75 | Upgrade
|
| Levered Free Cash Flow | -471.51 | -596.9 | -468.46 | -234.15 | -332.66 | -189.3 | Upgrade
|
| Unlevered Free Cash Flow | -462.25 | -592.17 | -465.75 | -232.23 | -332.66 | -189.3 | Upgrade
|
| Change in Net Working Capital | -17.88 | 107.34 | -12.43 | -80.68 | 74.72 | -82.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.